Understanding the Future of Medicine and What it Means for Your Company

Crosstree’s advisors have end-to-end experience in the pharma services, research, and development space, and has worked with companies positioned from discovery and preclinical, to clinical development and lab services, to supply and commercialization.

As pharmaceutical companies shift toward combination product development programs and more complex test-and-treat therapies, patient-centricity has become a focal point. Crosstree understands how each company supports the patient’s journey — either directly or secondarily by facilitating better research and development — and can identify the most viable buyers based on current and emerging needs.

Crosstree has provided buy- and sell-side financial guidance through the rise of targeted medicine. Today, Crosstree is spearheading transactions for innovative growth companies and established market leaders shifting toward precision and specialty medicine strategies.

For monthly coverage of M&A, recapitalization, and growth financing transactions and to stay apprised of valuations and trends, subscribe to Crosstree’s monthly BlueBooks.


Click image to view larger

Recent Deals

LongueVue Capital Partners Acquires Majority Stake in Summit Clinical Research to Accelerate SMO/IRO Growth
H.I.G. Capital Acquires Majority Stake in  Navitas Life Sciences to Accelerate CRO Growth
Lexitas Acquired by NovaQuest to Support Continued Growth and Capability Expansion
CCRC Recapitalized by Martis Capital Via Its Newly Formed Clinical Research Site Platform, Alcanza Clinical Research